Macarena Hernández Jiménez

Profesor Ayudante Doctor

Universidad Complutense de Madrid

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Macarena Hernández Jiménez is a Profesor Ayudante Doctor at Complutense University of Madrid, Spain. Her research primarily focuses on therapeutic applications of aptamers in neurological diseases, stroke treatment, and the impact of gut microbiota on cerebrovascular health. Recent contributions include studies on the cerebroprotective effects of DNA aptamers and their role in improving outcomes for ischemic stroke patients.

Articles (14)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Collaborators (8)

JESUS PRADILLO

LECTURER AND RESEARCHER

Universidad Complutense de Madrid

SPAIN

View details

OLIVIA HURTADO

Profesor Titular Universidad

Universidad Complutense de Madrid

SPAIN

View details

MARIA LAURA GARCIA-BERMEJO

SPAIN

View details

Joan Montaner

Universidad de Sevilla

SPAIN

View details

Maria Castelló-Ruiz

Senior Lecturer

University of Valencia

SPAIN

View details

María del Mar Castellanos

Head of Neurological Department

Complejo Hospitalario de Pontevedra

SPAIN

View details

María Hernández-Pérez

Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol

SPAIN

View details

Spencer D Proctor

University of Alberta

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Macarena Hernández Jiménez

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Changes in Infarct Volume and Cerebral Edema After Mechanical Thrombectomy in Patients With Stroke Randomized to ApTOLL or Placebo: A Secondary Analysis of APRIL Trial

Aptamers as new promising entities for therapeutics: our experience from the neurological diseases

Cerebroprotective Effects of the TLR4-Binding DNA Aptamer ApTOLL in a Rat Model of Ischemic Stroke and Thrombectomy Recanalization

Gut Microbiota, Bacterial Translocation, and Stroke: Current Knowledge and Future Directions

ApTOLL: A new therapeutic aptamer for cytoprotection and (re)myelination after multiple sclerosis

Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment

APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke.

Beneficial effect of TLR4 blockade by a specific aptamer antagonist after acute myocardial infarction.

Defective hippocampal neurogenesis underlies cognitive impairment by carotid stenosis-induced cerebral hypoperfusion in mice

Enhancing Enrollment in Acute Stroke Trials: Current State and Consensus Recommendations

First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers.

Defining a Target Population to Effectively Test a Neuroprotective Drug.

Influence of metabolic syndrome on post-stroke outcome, angiogenesis and vascular function in old rats determined by dynamic contrast enhanced MRI.

Targeting TLR4 with ApTOLL Improves Heart Function in Response to Coronary Ischemia Reperfusion in Pigs Undergoing Acute Myocardial Infarction.

Collaborators (8)

JESUS PRADILLO

OLIVIA HURTADO

MARIA LAURA GARCIA-BERMEJO

Joan Montaner

Maria Castelló-Ruiz

María del Mar Castellanos

María Hernández-Pérez

Spencer D Proctor

Make your next move.